Highly sensitive alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection. 2016

Gian Paolo Caviglia, and Maria Lorena Abate, and Elisa Petrini, and Silvia Gaia, and Mario Rizzetto, and Antonina Smedile
Departments of Medical Sciences, University of Turin.

OBJECTIVE Hepatocellular carcinoma (HCC) develops with high incidence in patients with chronic liver disease (CLD), and particularly in those with cirrhosis. Currently, diagnosis and surveillance are mainly based on imaging methods. The aim of this study was to evaluate the diagnostic accuracy of highly sensitive measurement of α-fetoprotein (AFP), Lens culinaris agglutinin-reactive fraction of AFP (AFP-L3) and des-γ-carboxyprothrombin (DCP) alone and in combination, for HCC detection. In addition, a recently proposed statistical model, including these three biomarkers plus sex and age, the GALAD model, was applied. METHODS In a total of 98 patients (44 CLD patients without HCC [23 men, 21 women; mean age, 53.2 ± 13.4 years] and 54 patients with HCC [45 men, nine women; 69.5 ± 9.8 years]), AFP, AFP-L3 and DCP levels were determined using a highly sensitive assay on an μTASWako i30 immuno-analyzer. Areas under the curve (AUC), sensitivity and specificity were calculated and compared to assess diagnostic performance of the HCC biomarkers and of the GALAD model. RESULTS AFP, AFP-L3 and DCP serum levels were significantly elevated in HCC compared with CLD patients (P < 0.0001). AUC values were 0.891, 0.867 and 0.870, respectively. The combination of the three biomarkers resulted in an AUC of 0.947, whereas the GALAD model showed an AUC of 0.976 with a difference between AUC values of 0.029 (P = 0.028). CONCLUSIONS The combination of AFP, AFP-L3 and DCP is superior to a single biomarker in HCC detection. Furthermore, GALAD model performance is significantly higher than simple combination of these three biomarkers.

UI MeSH Term Description Entries

Related Publications

Gian Paolo Caviglia, and Maria Lorena Abate, and Elisa Petrini, and Silvia Gaia, and Mario Rizzetto, and Antonina Smedile
March 2020, The Journal of international medical research,
Gian Paolo Caviglia, and Maria Lorena Abate, and Elisa Petrini, and Silvia Gaia, and Mario Rizzetto, and Antonina Smedile
July 2021, World journal of gastroenterology,
Gian Paolo Caviglia, and Maria Lorena Abate, and Elisa Petrini, and Silvia Gaia, and Mario Rizzetto, and Antonina Smedile
August 1993, Liver,
Gian Paolo Caviglia, and Maria Lorena Abate, and Elisa Petrini, and Silvia Gaia, and Mario Rizzetto, and Antonina Smedile
January 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association,
Gian Paolo Caviglia, and Maria Lorena Abate, and Elisa Petrini, and Silvia Gaia, and Mario Rizzetto, and Antonina Smedile
May 2011, Cancer science,
Gian Paolo Caviglia, and Maria Lorena Abate, and Elisa Petrini, and Silvia Gaia, and Mario Rizzetto, and Antonina Smedile
January 2011, Oncology,
Gian Paolo Caviglia, and Maria Lorena Abate, and Elisa Petrini, and Silvia Gaia, and Mario Rizzetto, and Antonina Smedile
March 2014, Journal of gastroenterology,
Gian Paolo Caviglia, and Maria Lorena Abate, and Elisa Petrini, and Silvia Gaia, and Mario Rizzetto, and Antonina Smedile
February 2019, Anticancer research,
Gian Paolo Caviglia, and Maria Lorena Abate, and Elisa Petrini, and Silvia Gaia, and Mario Rizzetto, and Antonina Smedile
February 2002, International journal of oncology,
Copied contents to your clipboard!